Revised SPC: Extavia (recombinant interferon beta-1b) 250 microgram/ml powder and solvent for solution for injection

SPC updated to note that cases of thrombotic microangiopathy (TMA), manifested as thrombotic thrombocytopenic purpura or haemolytic uraemic syndrome (including fatal cases), and cases of haemolytic anaemia not associated with TMA, have been reported with interferon beta products.

Source:

electronic Medicines compendium